Information  X 
Enter a valid email address

Proteome Sciences (PRM)

  Print   

Monday 16 March, 2020

Proteome Sciences

Notice of Results

RNS Number : 1825G
Proteome Sciences PLC
16 March 2020
 

  16 March 2020

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Notice of Results

 

The Directors of Proteome Sciences look forward to updating shareholders on the Company's performance, and on the outlook for 2020, at the time of announcing the 2019 full year results which are scheduled for release on 31 March 2020. 

Annual General Meeting

The Annual General Meeting of the Company will take place at the offices of Allenby Capital, 5 St Helen's Place, London EC3A 6AB, at 2.30pm on 29 April 2020.  Formal notice of such will be posted to shareholders with the annual report in April.

 

For further information please contact:

Proteome Sciences plc

Dr Ian Pike, Interim Chief Executive Officer

 

Tel: +44 (0)20 7043 2116

Richard Dennis, Chief Commercial Officer







Allenby Capital Limited (AIM Nominated Adviser & Broker) 

John Depasquale / Jeremy Porter

Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORFFFSFVTIVLII

a d v e r t i s e m e n t